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EDITORIAL
Mitochondria are organelles present in the cytosol 
of most eukaryotic organisms. They represent the 
cell’s main source of metabolic energy since they 
generate ATP (adenosine-triphosphate) through 
oxidative phosphorylation, a process involving the 
respiratory chain and the ATP synthase. Mitochondria 
also participate in other metabolic processes such 
as the synthesis of several cofactors and fatty acids, 
and have a role in metabolism regulation, cellular 
cycle control, ageing, and programmed cell death. 
These organelles originated approximately 2,500 
million years ago, when an alpha-proteobacterium 
was engulfed by another cell, probably an archaeon 
(archaebacterium) and a symbiotic relationship was 
thus established between the two micro-organisms. 
With time, intra-cellular alpha-proteobacteria gradually 
transferred their genetic material to the host’s 
nucleus, eventually giving rise to new organelles in 
the eukaryotic cell. For the aforementioned reasons, 
mitochondria preserve several remnants of their 
bacterial origin, among them, the presence of a small 
genome, which in humans is a circular molecule of 
16,600 base pairs, which we will herein refer to as 
mitochondrial DNA (mtDNA). Information contained 
within this genetic material represents less than 0.2% 
of the cells’ total genetic information; the remaining 
99.8% is found in the nuclear chromosomes (around 
19,000 genes which encode proteins). The human 
mtDNA contains 37 genes which encode ribosomal 
RNAs, transfer RNAs and 13 proteins that participate 
in oxidative phosphorylation. These set of highly 
hydrophobic membrane proteins are synthesized 
in mitochondrial ribosomes, integrated into the 
mitochondrial inner membrane, and assembled into the 
oxidative phosphorylation complexes. The rest of the 
1,500 to 2,000 proteins that are found in mitochondria 
are encoded in the nuclear genome, are synthesized 
in the cytosol, and penetrate the mitochondria through 
a transport apparatus built by protein receptors and 
transporters located in the mitochondrial membranes. 
Thus, mitochondria imports over 98% of all proteins 
required for its function, while it synthesizes for itself 
only a dozen proteins, which have an essential role 
in oxidative phosphorylation. In this scenario, I like to 
compare mitochondria with an oil-producing country 
that imports all its supplies and exports energy in 
exchange (oil or ATP).
Like any genetic material, mtDNA is prone to suffer 
mutations, some of which can elicit a heterogeneous 
spectrum of human diseases, called mitochondrial 
syndromes or mitochondrial encephalomyopathies. 
These pathological conditions mainly affect tissues 
and organs which have high energy demands, such as 
the brain, skeletal muscle and the endocrine system. 
The following are some of the clinical manifestations of 
mitochondrial diseases: muscle weakness, intolerance 
to exercise, blindness, mental retardation, dementia, 
progressive epilepsy, sensory neuropathies, ataxia 
and renal dysfunction. Mitochondrial alterations have 
also been related to other metabolic defects such as 
diabetes, obesity, cardiovascular diseases, neuro-
degenerative syndromes and cancer. Mitochondrial 
diseases are not restricted to the presence of 
mutations in mtDNA, they can also be originated by 
mutations in the nuclear DNA, especially those which 
affect either the structure or function of proteins which 
will eventually internalize into mitochondria. Herein we 
will only focus on mtDNA defects.
mtDNA is maternally inherited. Thus, we humans 
possess the same mtDNA as our mothers, our 
grandmothers, our great-grandmothers. This is due 
to the fact that mitochondria are present only in the 
www.medigraphic.org.mx
e142–e144
Revista Odontológica Mexicana 2015;19 (3): e142-e144 e143
www.medigraphic.org.mx
spermatozoid’s neck and are selectively destroyed 
once they reach the ovum, therefore, in general, there 
is no genetic contribution of paternal mtDNA during 
fertilization. Thus, several familial lineages that carry 
mitochondrial alterations exhibiting a clear maternal 
heredity pattern have been described.
To date, over 500 point mutations in mitochondrial 
genes related to human diseases have been 
reported, as well as several ablations and mtDNA 
duplications. Epidemiological studies have shown 
that approximately 1 out of 6,500 subjects may carry 
mtDNA pathogenic mutations. Mitochondria do not 
form anew in the cell; they can only be formed by the 
growth and division of pre-existing organelles. Even 
though there is a mitochondrial reticulum which is 
constantly fusing and dividing (experiencing ſ ssion), it 
is reckoned there are approximately 10 mtDNA copies 
in each mitochondria, and there are between 100 
and 1,000 mitochondria per cell (it is for this reason 
mtDNA is also useful in forensic sciences, since there 
are present more copies of mtDNA than of nuclear 
DNA, and therefore, is it possible to identify genetic 
material in very small samples, like in a hair follicle). 
For a mitochondrial disease to manifest itself, the point 
mutation in a mitochondrial gene must be present in 
at least 90% of the mtDNA population. Even though 
there are presently ongoing tools to transform nuclear 
DNA as well as various gene therapy protocols, to date 
there is no technique that allows the transformation of 
mtDNA of multi-cellular organisms, therefore, direct 
correction of human mtDNA mutations is not yet 
possible. Transformation of mtDNA in multi-cellular 
organisms continues to represent a challenge for both 
basic and clinical research. For the aforementioned 
reason, there is no effective treatment for mitochondrial 
diseases, except in those rare cases in which mtDNA 
mutation is solely found in one particular organ and 
there is a possibility of carrying out a transplant. Other 
therapeutic measures such as physical exercise and a 
variety of pharmacological therapies are only palliative 
measures, since they only mitigate some of the 
symptoms. The present lack of effective treatments 
for mitochondrial diseases has triggered exploration 
of several strategies to develop future gene therapies:
1. Selective inhibition of mutant mtDNA propagation. 
This approach at tempts to int roduce into 
mitochondria enzymes that are able to speciſ cally 
recognize and cut mutant mtDNA. In this way, only 
the mtDNA lacking mutations is able to propagate.
2. Mitochondrial expression vectors. This technique 
attempts to introduce recombinant mtDNA into 
the organelle, either whole or in fragments. It must 
contain a wild gene copy whose expression is 
controlled by mitochondrial gene promoters. This 
is a merely theoretical option, since, as mentioned 
beforehand, it is nowadays impossible to transform 
mitochondria in living multi-cellular organisms.
3. Allotopic expression. Mitochondrial genes are 
relocated to and expressed from the nucleus. 
The cytosol-synthesized wild-type protein is then 
internalized into mitochondria taking advantage of 
natural apparatus of protein import.
Allotopic expression is considered one of the 
most viable options for genetic treatment of diseases 
caused by mtDNA mutations, since there are already 
established techniques to introduce genetic material 
into the cell nucleus (using a variety of adenoviral 
vectors), therefore, in principle, the resulting protein 
should reach all the affected mitochondria present in 
the cell. The gene intended for allotopic expression 
must be modiſ ed in such a way that it is efſ ciently 
expressed in the nucleus. It must be noted that 
in humans, the genetic code and codon usage of 
mitochondrial genes differ from the ones of nuclear 
genes. For example, the UAG codon that encodes 
tryptophan in accordance with the mitochondrial 
genetic code is interpreted as a stop codon in the 
nuclear genetic code. Therefore, mitochondrial 
genes must be re-designed in such a way that 
their corresponding messenger RNAs are correctly 
translated in the cytosolic ribosomes. After it is 
synthesized, the protein is directed to the mitochondria 
by a signal sequence located in its amino-terminus, 
which is called mitochondrial targeting signal. These 
signals are constituted by a polypeptide chain of 20 
to 30 aminoacids that functions as a postal code, 
ensuring the dispatch of cytosol-synthesized proteins 
specifically to mitochondria and not to any other 
organelle in the cell. Targeting signals are recognized 
by the protein transporter complex located in the 
mitochondria’s internal and external membranes. 
After crossing both mitochondrial membranes and 
reaching the mitochondrial matrix, the signal is 
removed by a specific protease, giving rise to the 
mature protein. An alternative strategy developed 
in recent years is to allow the ingress of messenger 
RNAs into mitochondria, which seem to be imported 
through the same protein transport apparatus. 
These messenger RNAs also have speciſ c signals 
which direct them to the mitochondria. Once in the 
mitochondrial matrix, the messenger RNA can be 
translated by mitochondrial ribosomes and the 
corresponding protein is synthesized. Thus, proteins 
can directly integrate into the mitochondrial inner 
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membrane and assemble into its corresponding 
oxidative phosphorylation complex.
As stated above, to date, there is no effective 
therapy for mitochondrial diseases. Nevertheless, in 
recent years, interesting prevention alternatives have 
emerged. The ſ rst one is simply a prenatal diagnosis, 
which would allow a couple to decide whether or not 
to have children. The second one is spindle transfer, 
a technology based on the exchange of genetic 
materials followed by in vitro fertilization techniques.
When there is clear evidence of the presence 
of a mitochondrial mutation associated with a 
mitochondrial disease in a female, the technology 
to avoid this mutation to be inherited is currently 
available. This technology is based on the pioneering 
work of the group of Masahito Tachibana1,2 and 
colleagues working in several research institutes in 
Oregon (USA). Studies were first conducted with 
primates and then successfully carried out with human 
cells (Tachibana et al, 2009, 2013).2 In essence, 
ovules are taken from a donor female (with healthy 
mitochondria, no mutations) as well as from the 
female carrying mtDNA mutations (the mother who 
wants to bear a healthy child). The achromatic spindle 
is removed (the set of micro-tubules which go from 
the chromosomes centromeres to the centrioles at the 
poles during meiosis) from the donor’s ovule, that is 
to say all nuclear genetic material is eliminated from 
the ovule. In parallel, the achromatic spindle is also 
removed from the future mother’s ovule afƀ icted with 
mitochondrial mutations, and it is transferred to the 
donor’s ovule. In this fashion, «reconstructed» ovules, 
that contain the mother’s nuclear genetic material 
(intact), as well as the donor’s mitochondrial genetic 
material (also intact) are generated. The reconstructed 
ovule is fertilized in vitro, and embryogenesis is 
allowed to develop until the time when it can be 
safely implanted in the maternal uterus. A normal 
pregnancy will result, giving rise to a healthy baby who 
will have 49.9% of the father’s chromosomal genetic 
material, 49.9% of the mother’s chromosomal genetic 
material and only 0.2% of the donor’s genetic material 
(corresponding to the mitochondrial DNA). Therefore, 
stating tha  the baby is the product of «three parents» 
is not strictly true, although it does contain a genetic 
mosaic of three subjects. On February 3rd 2015, the 
House of Commons of the United Kingdom allowed 
this technique to be used in the clinic, giving the 
opportunity to females with mitochondrial mutations 
to bear healthy offspring. Thus, United Kingdom has 
become the ſ rst country to allow in vitro fertilization 
techniques to make use of the genetic material 
of a «second mother» in order to repair mutated 
mitochondrial DNA. Undoubtedly, this is another 
example where prevention advances faster than 
cure. United Kingdom has set an example for other 
countries to follow, including ours. Expedite legislation 
offers citizens to take advantage of the technological 
and scientiſ c advances at the earliest opportunity, and 
not after a long waiting period of maybe decades.
In spite of spectacular advances in mitochondrial 
disease prevention, allotopic expression is still 
an intellectual and experimental challenge which 
deserves further study. Successful  al lotopic 
expression will eventually set the bases for developing 
a genetic therapy which might give hope to patients 
suffering mitochondrial syndromes.
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